Arbutus Biopharma (ABUS) Misses Q3 EPS by 5c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79